Antibody-mediated depletion of CCL2 led to reduced immune cell infiltration to metastatic sites, while the use of CCL2 inhibitor reduced angiogenesis during liver fibrosis (Ehling et al., 2014). Here, CCL2 is linked to Hepatic fibrosis.